-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In the context of the current changes in the pharmaceutical industry environment, the flow of executives in pharmaceutical companies has accelerated significantly
.
According to statistics, since the beginning of 2021, more than 100 executives in the pharmaceutical industry have left, 25 of them are executives of multinational pharmaceutical companies, involving AstraZeneca, Eli Lilly, Merck, AbbVie, Roche and other large multinational companies For pharmaceutical companies, the main reasons for leaving are to seek external development and personal reasons
.
Judging from the whereabouts of these multinational pharmaceutical company executives after their departure, many multinational pharmaceutical companies represented by AstraZeneca, Eli Lilly, etc.
, since 2021, many executives who "leave" are seeking external development opportunities and go to the local area Pharmaceutical companies
.
Behind it, the competition for people in the pharmaceutical market is fierce, and the industry structure has ushered in new changes
.
For example, Ji Jing, the former vice president of China R&D of AstraZeneca, resigned on February 18, 2021, and later became the chief medical officer of Heyu Pharmaceutical; Dong Lijun, the former general manager of AstraZeneca, announced his resignation on July 23, 2021.
Luoxin Pharmaceutical was appointed as Deputy General Manager, Executive Vice President and Chief Operating Officer; in September 2021, Zhang Anwei, the former RGM of AstraZeneca East District and Chairman of the Sales Advisory Committee, later served as General Manager of Sales of Luoxin Pharmaceutical's innovative drug direct sales business, group Vice President; in November, Du Haochen, the former vice president of AstraZeneca China and the head of the county business department, resigned, and he chose to join BeiGene as the head of the broad market; in December, Yin, the former general manager of AstraZeneca's China Oncology Division Min resigned, and he joined BeiGene like Du Haochen as the chief commercial officer of BeiGene Greater China
.
Wang Yizhe, head of global research and development of Lilly's anti-tumor products, will leave in May 2021 and will be the CEO of Liantuo Biosciences after leaving.
TuoBio serves as the general manager of China
.
Qian Wei, general manager of Roche China's First Division of Oncology, announced his resignation on May 28, 2021, and will go to Junshi Biotechnology as chief commercial officer
.
In addition, Luo Wanli, the former China President of Merck & Co.
, chose to be the CEO of Star Pharmaceuticals after leaving in June last year; Li Xiaoyan, the former executive director of clinical development at AbbVie, resigned.
In January 2021, Weimou Bio appointed Li Xiaoyan as the CMO
.
From the perspective of the above-mentioned flow of executives, local innovative drug companies are becoming a gathering place for the return of talents
.
In recent years, with the continuous advancement of domestic medical reform, the local innovation environment has been improving, and local innovative drug companies have continued to rise.
There is an urgent need for talents, especially those companies with rich R&D pipelines, urgently need experienced talents to join in to control innovative drugs.
product launch
, etc.
At the same time, in recent years, with the continuous improvement of the strength of local innovative drugs, more and more companies have begun to deploy internationalization.
Talent joined, responsible for new drug research and development and global clinical development strategy and execution
.
In addition, in the context of the vigorous development of the local innovative drug industry and the vast blue ocean of the market, the competition among innovative drug companies has become increasingly fierce, which also makes many companies spend a lot of money to recruit talents to join them
.
From the perspective of the overall environment, domestic treatment of high-level talents and environmental policies have also improved, which may be one of the reasons why talents from multinational pharmaceutical companies have turned to local companies
.
In general, it has become a trend for senior executives of multinational pharmaceutical companies to regard Chinese local pharmaceutical companies as their "new home", and the industry pattern may undergo major changes in the future
.
.
According to statistics, since the beginning of 2021, more than 100 executives in the pharmaceutical industry have left, 25 of them are executives of multinational pharmaceutical companies, involving AstraZeneca, Eli Lilly, Merck, AbbVie, Roche and other large multinational companies For pharmaceutical companies, the main reasons for leaving are to seek external development and personal reasons
.
Judging from the whereabouts of these multinational pharmaceutical company executives after their departure, many multinational pharmaceutical companies represented by AstraZeneca, Eli Lilly, etc.
, since 2021, many executives who "leave" are seeking external development opportunities and go to the local area Pharmaceutical companies
.
Behind it, the competition for people in the pharmaceutical market is fierce, and the industry structure has ushered in new changes
.
For example, Ji Jing, the former vice president of China R&D of AstraZeneca, resigned on February 18, 2021, and later became the chief medical officer of Heyu Pharmaceutical; Dong Lijun, the former general manager of AstraZeneca, announced his resignation on July 23, 2021.
Luoxin Pharmaceutical was appointed as Deputy General Manager, Executive Vice President and Chief Operating Officer; in September 2021, Zhang Anwei, the former RGM of AstraZeneca East District and Chairman of the Sales Advisory Committee, later served as General Manager of Sales of Luoxin Pharmaceutical's innovative drug direct sales business, group Vice President; in November, Du Haochen, the former vice president of AstraZeneca China and the head of the county business department, resigned, and he chose to join BeiGene as the head of the broad market; in December, Yin, the former general manager of AstraZeneca's China Oncology Division Min resigned, and he joined BeiGene like Du Haochen as the chief commercial officer of BeiGene Greater China
.
Wang Yizhe, head of global research and development of Lilly's anti-tumor products, will leave in May 2021 and will be the CEO of Liantuo Biosciences after leaving.
TuoBio serves as the general manager of China
.
Qian Wei, general manager of Roche China's First Division of Oncology, announced his resignation on May 28, 2021, and will go to Junshi Biotechnology as chief commercial officer
.
In addition, Luo Wanli, the former China President of Merck & Co.
, chose to be the CEO of Star Pharmaceuticals after leaving in June last year; Li Xiaoyan, the former executive director of clinical development at AbbVie, resigned.
In January 2021, Weimou Bio appointed Li Xiaoyan as the CMO
.
From the perspective of the above-mentioned flow of executives, local innovative drug companies are becoming a gathering place for the return of talents
.
In recent years, with the continuous advancement of domestic medical reform, the local innovation environment has been improving, and local innovative drug companies have continued to rise.
There is an urgent need for talents, especially those companies with rich R&D pipelines, urgently need experienced talents to join in to control innovative drugs.
product launch
, etc.
At the same time, in recent years, with the continuous improvement of the strength of local innovative drugs, more and more companies have begun to deploy internationalization.
Talent joined, responsible for new drug research and development and global clinical development strategy and execution
.
In addition, in the context of the vigorous development of the local innovative drug industry and the vast blue ocean of the market, the competition among innovative drug companies has become increasingly fierce, which also makes many companies spend a lot of money to recruit talents to join them
.
From the perspective of the overall environment, domestic treatment of high-level talents and environmental policies have also improved, which may be one of the reasons why talents from multinational pharmaceutical companies have turned to local companies
.
In general, it has become a trend for senior executives of multinational pharmaceutical companies to regard Chinese local pharmaceutical companies as their "new home", and the industry pattern may undergo major changes in the future
.
